Aligning Research to Impact Autism

Name

Aligning Research to Impact Autism

Legal name

Aligning Research to Impact Autism

Website

https://ariaroadmap.org

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biomedical Research Funding (Autism and Neurodevelopmental Conditions)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Individual and Family Services (624190), Professional, Scientific, and Technical Services (54)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Autism Communication Support (AAC, Pragmatics & Language) (EDAKAKAG), Research Administration & Grants Management Support (Pre/Post-Award, Compliance) (EDAEALAO)

Keywords

• Biomedical research funding
• Autism clinical trials
• Genetic medicine research
• Neuroscience research hubs
• Open science infrastructure

GTM type

B2B

Offering type

Services

Cost components

Others, Operations, Personnel, Technology or R&D

Revenue model

1. Philanthropic Funding (CNS Quest): ARIA is funded as part of CNS Quest, a program of the Sergey Brin Family Foundation and Catalyst4. CNS Quest is an initiative to accelerate discoveries, advance treatments and care, and improve daily lives of people impacted by autism, Parkinson's disease, bipolar disorder, and other CNS conditions.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

ARIA is a philanthropic research funding and coordination initiative that distributes multi-year grants and shared centralized services to academic medical centers and community organizations to accelerate clinical and translational autism research. It operates six interconnected research hubs covering genetic medicines, protein-protein interactions, human developmental neurobiology, neurosensing and neuromodulation, functional communication, and the IMPACT Network clinical trials infrastructure across 20+ sites in the US, UK, and Canada. Supported services include a clinical coordinating center, data coordinating center, biobank, whole-genome sequencing provider, and single IRB (BRANY).

Product overview

ARIA is an integrated research ecosystem comprising six research hubs (IMPACT Network, Genetic Medicines, Protein-Protein Interactions, Human Developmental Neurobiology, Neurosensing and Neuromodulation, and Functional Communication) supported by five centralized services (Clinical Coordinating Center, Data Coordinating Center, Biobank, Whole Genome Sequence Provider, and Single IRB). The initiative connects emerging research, insights, and promising technologies to build an integrated ecosystem that bridges clinical and translational research for autism.

Differentiator

Problem solved

Functional benefit

Products and services

• IMPACT Network
• Genetic Medicines Hub
• Protein-Protein Interactions Hub
• Human Developmental Neurobiology Hub
• Neurosensing and Neuromodulation Hub
• Functional Communication Hub
• Clinical Coordinating Center
• Data Coordinating Center
• ARIA Biobank
• Whole Genome Sequence Provider
• Single Institutional Review Board (sIRB)
• IMPACT-Ready Study
• Open Science Infrastructure

Quantifiable outcome

• Over 200 multidisciplinary experts engaged in developing the research roadmap
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature9 records

Partnerships

31 partnerships are on record, tiered core and flagship.

• Autism Science Foundation (ASF)coreStrategic or Co-development PartnerCommunity collaborator supporting the expansion of the Next Gen Sibs Program to include more sites and second-degree relative relations. Project aims to improve early detection by determining clinical features associated with autism in infants with family history of autism.
• N=1 CollaborativecoreStrategic or Co-development PartnerWorking to standardize sharing of clinical data for rare genetic neurodevelopmental diseases with goal of advancing individualized precision drug development. Award supports development of the Individualized Medicine Knowledge Base integrating gene registry with preclinical and clinical databases.
• Simons SearchlightcoreStrategic or Co-development PartnerProgram funded by Simons Foundation that aims to better understand neurodevelopmental disorders by collecting high-quality standardized natural history data and building partnerships between researchers, industry, and families. Collaboration supports advancing clinical trial readiness across genetic communities.
• Lasso InformaticscoreTechnology or IntegrationImplements the Data Coordinating Center (DCC) to ingest and harmonize clinical and quantitative phenotyping data collected at IMPACT Network sites. Coordinates support from multiple partners to ensure high-quality data for future discoveries.
• Bridge AnalyticscoreTechnology or IntegrationProvides long-term, secure, cloud-based analytical platform and data repository enabling scientific research community to access ARIA data for future analyses across many datasets.
• BRANY (Biomedical Research Alliance of New York)coreTechnology or IntegrationImplements the Single Institutional Review Board (sIRB) to streamline multi-site IRB approvals for multi-site clinical studies. Ensures unified ethical review, parallel approvals across institutions, and centralized reliance management.
• Coalition for Aligning Science (CAS)flagshipStrategic or Co-development PartnerARIA is a funding initiative implemented by the Coalition for Aligning Science. CAS provides scientific strategy and program implementation to accelerate biomedical discovery and translate research insights into therapeutic impact. ARIA Managing Director Ekemini Riley is also Founder and CEO of CAS.
• Harvard UniversitycoreStrategic or Co-development PartnerHuman Developmental Neurobiology Hub Co-Lead Paola Arlotta is Golub Family Professor at Harvard Stem Cell Institute. Neurosensing projects involve researchers including Edward Chang from UCSF Weill Institute.
• Yale School of MedicinecoreStrategic or Co-development PartnerMultiple ARIA leaders from Yale including Chief Scientific Advisor Matthew State, Nenad Sestan (Human Developmental Neurobiology Co-Lead), Murat Günel (Neurosensing and Neuromodulation Co-Lead), and John Krystal (Scientific Advisory Board). Yale site joining IMPACT Network.
• UCSF (University of California, San Francisco)coreStrategic or Co-development PartnerMultiple ARIA leaders from UCSF including Nevan Krogan (Protein-Protein Interactions Co-Lead), Timothy Yu (Genetic Medicines Co-Lead), Andrew Krystal, and Edward Chang (Neurosensing projects).
• Stanford UniversitycoreStrategic or Co-development PartnerKarl Deisseroth (Stanford Medicine) leads Temporal Dynamics project in Neurosensing and Neuromodulation Hub. Rob Malenka serves on Scientific Advisory Board.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development PartnerCHOP-Penn team among initial sites in IMPACT Network Wave 1. Raquel Gur leads Penn-CHOP Research Integration.
• Boston Children's HospitalcoreStrategic or Co-development PartnerBoston Children's is IMPACT Boston site. Mustafa Sahin and Shafali Jeste (Clinical Coordinating Center Co-Leads) are affiliated. Erika Augustine trained there.
• Marcus Autism Center, Children's Healthcare of AtlantacoreStrategic or Co-development PartnerIMPACT Atlanta site led by Ami Klin (Georgia Research Alliance Eminent Scholar, Director of Marcus Autism Center). Warren Jones serves as Biomarker Research Lead.
• University of North Carolina at Chapel HillcoreStrategic or Co-development PartnerIMPACT Carolina site. Mark Shen serves as Lead PI.
• University of Colorado Anschutz Medical Campus & Children's Hospital ColoradocoreStrategic or Co-development PartnerIMPACT Colorado site. Tim Benke serves as Lead PI.
• Children's Hospital Los Angeles & UCLAcoreStrategic or Co-development PartnerIMPACT LA site. Jonathan Santoro serves as Lead PI. Shafali Jeste is Professor at USC Keck School of Medicine and Chief of Neurology at CHLA.
• Weill Cornell Medicine & Columbia UniversitycoreStrategic or Co-development PartnerIMPACT New York site. Jeremy Veenstra Vanderweele serves as Lead PI. Awarded $17.25 million grant to study profound autism.
• Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development PartnerIMPACT Ohio site. Craig Erickson serves as Lead PI. Awarded $17.25 million grant for longitudinal autism research.
• Seattle Children's Hospital & University of WashingtoncoreStrategic or Co-development PartnerIMPACT Seattle site. Sara Webb serves as Lead PI. Awarded up to $17.25 million grant to advance autism research.
• Texas Children's Hospital & Baylor College of MedicinecoreStrategic or Co-development PartnerIMPACT Texas site. Jimmy Holder serves as Lead PI. Awarded up to $17.25 million to join IMPACT Network.
• University of Oxford & King's College LondoncoreStrategic or Co-development PartnerIMPACT UK site (Wave 1b). Oxford University and King's College London join IMPACT Network study to advance understanding of profound autism.
• Holland Bloorview Kids Rehabilitation Hospital & Hospital for Sick Children (SickKids)coreStrategic or Co-development PartnerIMPACT Toronto site. Evdokia Anagnostou serves as Lead PI. Awarded up to USD $17.25 million international research grant.
• University of California, San FranciscocoreStrategic or Co-development PartnerIMPACT San Francisco site (Wave 2).
• Stanford UniversitycoreStrategic or Co-development PartnerIMPACT Stanford site (Wave 2).
• Rush University & University of OklahomacoreStrategic or Co-development PartnerIMPACT Chicago site (Wave 2).
• University of Kansas & Children's Mercy HospitalcoreStrategic or Co-development PartnerIMPACT Kansas City site (Wave 2).
• University of MinnesotacoreStrategic or Co-development PartnerIMPACT Minnesota site (Wave 2). Meghan Swanson (Functional Communication Co-Lead) is affiliated.
• Yale UniversitycoreStrategic or Co-development PartnerIMPACT New Haven site (Wave 2). Murat Günel (Neurosensing and Neuromodulation Co-Lead) is affiliated with Yale School of Medicine.
• Washington University in St. LouiscoreStrategic or Co-development PartnerIMPACT St. Louis site (Wave 2).
• Kennedy Krieger InstitutecoreStrategic or Co-development PartnerWave 1b site. Erika Augustine (Scientific Advisory Board) is affiliated.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Autism Speaks: Autism Speaks is the largest autism advocacy and research funding organization, with a much broader mission spanning advocacy, services, and research. It is a broad incumbent in autism research funding with significantly larger public profile and revenue than ARIA.

Direct peers

• Simons Searchlight: Simons Searchlight is a Simons Foundation program building natural history studies for rare genetic neurodevelopmental conditions. It is an ARIA community collaborator and overlapping peer in deep phenotyping and clinical trial readiness for genetic autism.
• Simons Foundation Autism Research Initiative (SFARI): SFARI is the largest private funder of autism research, operating its own clinical networks (SPARK, Simons Searchlight) and funding genetic/biological autism research. It is the most direct competitor to ARIA in autism research funding and infrastructure, with overlapping genetic research priorities and shared community collaborators.
• Autism Science Foundation (ASF): ASF is a major nonprofit autism research funding organization that supports basic and translational autism research as well as the Next Gen Sibs program (with which ARIA partners). Comparable operating model as a research funder in the same disease area.
• Aligning Science Across Parkinson's (ASAP): ASAP is a sister initiative under the same Coalition for Aligning Science leadership and Sergey Brin Family Foundation funding, focused on Parkinson's disease. It pioneered the same integrated research hub + clinical network model that ARIA implements, making it the most structurally comparable peer.
• N=1 Collaborative: N=1 Collaborative is a nonprofit developing individualized therapies for rare genetic diseases, including the Individualized Medicine Knowledge Base that ARIA co-funds. It is a direct peer in ultra-rare genetic neurodevelopmental therapeutic development.
• SPARK (Simons Foundation): SPARK is a large-scale autism research initiative and genetic registry recruiting tens of thousands of families—comparable to ARIA's IMPACT-Ready Study cohort but at much larger scale. Both are building patient cohorts with genetic data for autism research.

Emerging players

• Cure Rare Disease: Cure Rare Disease is a nonprofit developing antisense oligonucleotide and gene therapies for ultra-rare genetic diseases including some forms of autism. It is comparable in mission and modality (ASO-based genetic medicines) to ARIA's Genetic Medicines Hub.
• Healx: Healx is an AI-driven drug discovery company focused on rare diseases including Fragile X syndrome and other neurodevelopmental conditions. Comparable AI-driven approach to genetic neurodevelopmental therapeutic development, though operating as a commercial entity rather than a research funder.

Others

• Coalition for Aligning Science (CAS): CAS is the parent organization that implements ARIA and other Aligning Science initiatives (ASAP, ADAPT). It is the operating backbone and provides scientific strategy; ARIA is effectively a program of CAS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ariaroadmap

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aligning Research to Impact Autism